Indirect Purchasers' $35M Settlement Gets Final Approval In Flonase Antitrust Case

Indirect Purchasers' $35M Settlement Gets Final Approval In Flonase Antitrust Case

PHILADELPHIA - A federal judge in Pennsylvania on June 19 granted final approval to a $35 million settlement between prescription drug Flonase manufacturer GlaxoSmithKline PLC (GSK) and indirect purchasers on the indirect purchasers' claims that GSK filed a series of sham citizen petitions with the Food and Drug Administration to delay the entry of a generic version of Flonase into the market (In re Flonase Antitrust Litigation $(Indirect Purchaser Actions$), No. 08-3301, E.D. Pa.).

Find full version on lexis Advance®
Access this news story on lexis.com®